Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Moberg Pharma AB (publ)    MOB   SE0013121340

MOBERG PHARMA AB (PUBL)

(MOB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Moberg Pharma : publishes audited interim report for the period July 2019 - September 2020

11/27/2020 | 09:26am EST

STOCKHOLM, November 27[th], 2020 - On November 10[th], 2020, Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") published its interim report for the period July 2019 - September 2020. The Company today publishes an audited interim report for the same period. The audit has not resulted in any adjustments to the financial numbers published on November 10[th], 2020.

The audit of the interim report has been carried out due to the contemplated rights issue in the Company and the prospectus that is being prepared in connection thereto. The audited interim report is available in Swedish on the Company's website: https://www.mobergpharma.se/investerare/prospekt

For additional information, please contact:
Anna Ljung, CEO, Phone: + 46 70 766 60 30, e-post: anna.ljung@mobergpharma.se
Mark Beveridge, VP Finance, Phone: + 46 76 805 82 88, e-post: mark.beveridge@mobergpharma.se

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company's main asset, MOB-015, is a novel topical treatment for onychomycosis, with recently completed phase 3 trials in more than 800 patients. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis, intended to be spun off in the separate company OncoZenge. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the Company's shares are listed on the Small Cap list of Nasdaq Stockholm (OMX: MOB).

https://news.cision.com/moberg-pharma/r/moberg-pharma-publishes-audited-interim-report-for-the-period-july-2019---september-2020,c3245326

https://mb.cision.com/Main/1662/3245326/1341156.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English

All news about MOBERG PHARMA AB (PUBL)
01/18MOBERG PHARMA : announces the last day of trading in BTU and the first trading d..
PU
01/18MOBERG PHARMA : OncoZenge announces issue of European Patent related to BupiZeng..
PU
01/14MOBERG PHARMA : announces the last day of trading in BTU and the first trading d..
AQ
01/07MOBERG PHARMA : OncoZenge announces issue of European Patent related to BupiZeng..
AQ
2020MOBERG PHARMA : rights issue of MSEK 150 is fully subscribed and no issue guaran..
PU
2020MOBERG PHARMA : rights issue of MSEK 150 is fully subscribed and no issue guaran..
AQ
2020MOBERG PHARMA : OncoZenge expands the board with Hilde Furberg
PU
2020MOBERG PHARMA : OncoZenge raises MSEK 10 ahead of spin-off and separate listing
AQ
2020MOBERG PHARMA : Invitation to market update in Moberg Pharma on November 25
PU
2020MOBERG PHARMA : publishes prospectus relating to the rights issue
AQ
More news
Financials
Sales 2020 - - -
Net income 2020 9,51 M 1,14 M 1,14 M
Net Debt 2020 25,0 M 2,99 M 2,99 M
P/E ratio 2020 13,9x
Yield 2020 -
Capitalization 301 M 36,0 M 35,9 M
EV / Sales 2020 -
EV / Sales 2021 45,0x
Nbr of Employees 11
Free-Float 83,0%
Chart MOBERG PHARMA AB (PUBL)
Duration : Period :
Moberg Pharma AB (publ) Technical Analysis Chart | MOB | SE0013121340 | MarketScreener
Technical analysis trends MOBERG PHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 1
Average target price 96,50 SEK
Last Close Price 6,99 SEK
Spread / Highest target 1 281%
Spread / Average Target 1 281%
Spread / Lowest Target 1 281%
EPS Revisions
Managers and Directors
NameTitle
Anna Ljung Chief Executive Officer
Peter Gunnar Maurits Wolpert Executive Chairman
Mark Beveridge Vice President-Finance
Torbjörn Wärnheim Deputy CEO, SVP-Research & Development
Cindy Wong Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
MOBERG PHARMA AB (PUBL)-1.46%36
JOHNSON & JOHNSON6.67%448 796
ROCHE HOLDING AG4.51%312 213
NOVARTIS AG0.81%214 457
PFIZER INC.-1.55%207 384
MERCK & CO., INC.-1.89%203 035